Kexing Biopharm Full Year 2024 Earnings: Misses Expectations

Kexing Biopharm (SHSE:688136) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥1.41b (up 12% from FY 2023).
• Net income: CN¥31.5m (up from CN¥190.3m loss in FY 2023).
• Profit margin: 2.2% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue.
• EPS: CN¥0.16 (up from CN¥0.96 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kexing Biopharm Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 7.3%. Earnings per share (EPS) also missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 5.3% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Kexing Biopharm that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.